Pfizer touts positive topline data for RSV vaccine Abrysvo
Abrysvo was found to be safe in immunocompromised adults at risk for developing RSV-associated lower respiratory tract disease.
13 August 2024
13 August 2024
Abrysvo was found to be safe in immunocompromised adults at risk for developing RSV-associated lower respiratory tract disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.